Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.
AgomAb Therapeutics has filed for an initial public offering (IPO) in the U.S., looking to tap public markets to fund the next stage of development for its pipeline in fibrotic and inflammatory diseases. The Antwerp-based biotech said in its filing with the U.S. Securities and Exchange Commission that it plans to list its shares on Nasdaq under the ticker AGMB.
Another strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.
123rf.com/Iculig